EcoDrugPlus

Guanylate Cyclase 1 Soluble Subunit Alpha 1

Ensembl ID : ENSATEG00000016727
Gene Symbol: GUCY1A1
3 Cross references
201 Possible Orthologues:

Guanylate Cyclase 1 Soluble Subunit Alpha 2

Ensembl ID : ENSATEG00000007937
Gene Symbol: GUCY1A2
4 Cross references
204 Possible Orthologues:

Guanylate Cyclase 1 Soluble Subunit Beta 1

Ensembl ID : ENSATEG00000016751
Gene Symbol: GUCY1B1
1 Cross references
211 Possible Orthologues:

Heat Shock Protein 90, Alpha (Cytosolic), Class A Member 1, Tandem Duplicate 2

Ensembl ID : ENSATEG00000000852
Gene Symbol: HSP90AA1.2
3 Cross references
317 Possible Orthologues:

Heat Shock Protein 90, Alpha (Cytosolic), Class B Member 1

Ensembl ID : ENSATEG00000017267
Gene Symbol: HSP90AB1
3 Cross references
355 Possible Orthologues:

High Mobility Group Box 1a

Ensembl ID : ENSATEG00000004559
Gene Symbol: HMGB1A
2 Cross references
498 Possible Orthologues:

High Mobility Group Protein B1-Like

Ensembl ID : ENSATEG00000013167
Gene Symbol: LOC113173213
3 Cross references
512 Possible Orthologues:

Histamine Receptor H1

Ensembl ID : ENSATEG00000024985
Gene Symbol: HRH1
3 Cross references
186 Possible Orthologues:

Histone Deacetylase 1

Ensembl ID : ENSATEG00000007393
Gene Symbol: HDAC1
3 Cross references
250 Possible Orthologues:

Histone Deacetylase 10

Ensembl ID : ENSATEG00000019120
Gene Symbol: HDAC10
3 Cross references
181 Possible Orthologues:

Histone Deacetylase 11

Ensembl ID : ENSATEG00000004276
Gene Symbol: HDAC11
3 Cross references
198 Possible Orthologues:

Histone Deacetylase 2

Ensembl ID : ENSATEG00000012237
Gene Symbol: HDAC2
4 Cross references
205 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).